Literature DB >> 9317060

Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.

G Sahagun1, K G Benner, R Saxon, R E Barton, J Rabkin, F S Keller, J Rosch.   

Abstract

OBJECTIVES: One hundred consecutive patients with recurrent or refractory acute variceal hemorrhage treated with a transjugular intrahepatic portosystemic shunt (TIPS) from June 1990 to June 1993 at Oregon Health Sciences University or the Portland Veterans Affairs Medical Center were evaluated to assess shunt patency and clinical outcome, including complications of TIPS, rebleeding, and survival.
METHODS: Success of shunt placement, reduction in portal pressure, complications, survival, recurrent hemorrhage, severity of ascites, hepatic encephalopathy before and after TIPS, and shunt patency were assessed in each patient.
RESULTS: The mean follow-up period was 17.7 months (range, 0.1-56.7 months). TIPS was successfully completed in all patients, with a mean reduction in portosystemic gradient from 24 to 11 mm Hg. Major complications occurred in 11 patients, including one death. Survival after TIPS was 85% at 30 days, 71% at 1 yr, and 56% at 2 yr. Variceal bleeding stopped within 24 hours after TIPS in all eight patients with active hemorrhage. Recurrent variceal hemorrhage occurred in 18 patients at a mean of 4.3 months (range, 1-713 days) after TIPS. The cumulative rate of recurrent variceal bleeding was 20% at 1 yr and 25% at 2 yr after TIPS. Recurrent variceal bleeding was associated with shunt stenosis or occlusion in all patients with endoscopically documented variceal hemorrhage, which was successfully managed by reopening obstructed shunts and performing variceal embolization. The prevalence of ascites was significantly reduced among surviving patients evaluated 3 months after TIPS (67 vs 25%, p < 0.005). Three months after TIPS, the incidence of new or worsening hepatic encephalopathy was 20%, but encephalopathy improved in an equal proportion of patients. Seventy-three of 77 (95%) shunts examined for patency were open at the last follow-up examination. However, most shunts required intervention to maintain patency, and only 48% (37 of 77) were primarily patent at a mean of 168 days (range, 2-538 days) of follow-up. Shunt stenosis or occlusion, as determined by venography, became increasingly frequent with longer follow-up (52% at 3-9 months and 70% at 9-15 months).
CONCLUSIONS: TIPS is effective in lowering elevated portal pressures in patients with refractory variceal hemorrhage, has acceptable postprocedure complication and mortality rates, ameliorates ascites, and in, a minority of patients, worsens encephalopathy. Shunt stenosis occurs in the majority of patients but can be effectively treated by interventional techniques to maintain patency. The incidence of recurrent variceal hemorrhage is low and is associated with shunt stenosis or occlusion.

Entities:  

Mesh:

Year:  1997        PMID: 9317060

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

Review 1.  Current status of transjugular intrahepatic portosystemic shunts.

Authors:  N H Patel; N Chalasani; R M Jindal
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

2.  Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization.

Authors:  Ron C Gaba; James T Bui; Scott J Cotler; Eric R Kallwitz; Olga T Mengin; Brandon K Martinez; Jaime L Berkes; Tami C Carrillo; M Grace Knuttinen; Charles A Owens
Journal:  Hepatol Int       Date:  2010-08-06       Impact factor: 6.047

3.  Usefulness of multi-detector helical CT with multiplanar reconstruction for depicting the duodenal varices with multiple collateral shunt vessels.

Authors:  Shuntaro Yoshida; Hirotsugu Watabe; Masaaki Akahane; Yusuke Kyoden; Hanako Ishikawa; Atsuo Yamada; Takafumi Sugimoto; Miki Ohta; Keiji Ogura; Yutaka Yamaji; Kuni Ohtomo; Norihiro Kokudo; Kazuhiko Koike; Masao Omata
Journal:  Hepatol Int       Date:  2010-07-24       Impact factor: 6.047

Review 4.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

5.  Transjugular Intrahepatic Portosystemic Shunt (TIPS) versus Balloon-occluded Retrograde Transvenous Obliteration (BRTO) for the Management of Gastric Varices.

Authors:  Wael E A Saad; Michael D Darcy
Journal:  Semin Intervent Radiol       Date:  2011-09       Impact factor: 1.513

Review 6.  Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

Authors:  Romaric Loffroy; Louis Estivalet; Violaine Cherblanc; Sylvain Favelier; Pierre Pottecher; Samia Hamza; Anne Minello; Patrick Hillon; Pierre Thouant; Pierre-Henri Lefevre; Denis Krausé; Jean-Pierre Cercueil
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

7.  Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.

Authors:  Hauke S Heinzow; Philipp Lenz; Michael Köhler; Frank Reinecke; Hansjörg Ullerich; Wolfram Domschke; Dirk Domagk; Tobias Meister
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

8.  Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects.

Authors:  C Gazzera; D Righi; F Valle; A Ottobrelli; M Grosso; G Gandini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

Review 9.  Outcomes of TIPS for Treatment of Gastroesophageal Variceal Hemorrhage.

Authors:  Ahmad Parvinian; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

10.  Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.

Authors:  B Angermayr; M Cejna; F Karnel; M Gschwantler; F Koenig; J Pidlich; H Mendel; L Pichler; M Wichlas; A Kreil; M Schmid; A Ferlitsch; E Lipinski; H Brunner; J Lammer; P Ferenci; A Gangl; M Peck-Radosavljevic
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.